Aveva: Can Virtual Replicas Save Billions in Healthcare Inefficiency?
What is Aveva? AVEVA provides a portfolio of digital twin and industrial intelligence solutions that create contextualised, real-time virtual replicas of physical assets, processes, and plants. By linking engineering models, operational historian data, IoT telemetry, and analytics, AVEVA enables simulation, predictive maintenance, scenario planning, and performance optimisation across the asset lifecycle — from design and […]
Feature Categories
What is Aveva?
AVEVA provides a portfolio of digital twin and industrial intelligence solutions that create contextualised, real-time virtual replicas of physical assets, processes, and plants. By linking engineering models, operational historian data, IoT telemetry, and analytics, AVEVA enables simulation, predictive maintenance, scenario planning, and performance optimisation across the asset lifecycle — from design and construction to operations and decommissioning. In life sciences and pharmaceutical manufacturing,
AVEVA digital twins support process validation, capacity planning, batch optimisation, and “virtual patient” or process simulations to accelerate scale-up and reduce quality events. The platform supports hybrid deployments (on-prem + cloud), role-based visualization, and integration with control and enterprise systems to drive measurable operational and capital efficiencies.
Why Leading Healthcare Teams Trust Aveva?
- Recognized as Best Global Industrial Software Solutions Provider in 2021 by Corporate Vision Magazine; member of United Nations Global Compact with FTSE4Good recognition
- Complies with ISO 27001, ISO 27017, ISO 27018, AICPA SOC 2, IEC 62443, and GDPR standards for information security and data protection
- Encrypts all data communications using AES 256-bit encryption with SSL/TLS over HTTPS; employs logical segregation in multi-tenant cloud architecture to isolate customer data
- Maintains transparent data governance policies with clear procedures for data subject rights; implements Secure Development Lifecycle processes with rigorous security testing
- Acquired OSIsoft in August 2020 for $5 billion; completed full acquisition by Schneider Electric on January 18, 2023, valuing total company at approximately £9.48 billion
- Sanofi uses Aveva's digital twin technology with quantitative systems pharmacology to model human patients for faster drug development; regulatory bodies recognise computer modelling results for safety and efficacy assessment
Top 3 Pain Points Aveva Fixes in Healthcare
| Problem / Challenge | How AVEVA Solves It |
|---|---|
| 1. Inefficient facility and equipment management | Creates real-time digital replicas of medical facilities, labs, and manufacturing assets, allowing predictive maintenance, reduced downtime, and improved equipment reliability. |
| 2. Fragmented operational data and limited visibility | Integrates data from IoT sensors, engineering systems, and process control platforms into a unified digital twin, giving clinicians, engineers, and administrators a single source of truth for decision-making. |
| 3. High cost and risk in process optimisation | Enables simulation and scenario testing of healthcare or pharmaceutical processes before implementation, reducing waste, minimizing compliance risks, and optimizing resource utilization. |
Feature Category Summary: AVEVA
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | AVEVA PI System and AVEVA Connect are used by pharmaceutical and life sciences manufacturers to centralise batch processing data and automate data integrity checks in support of regulatory compliance and product quality, but there is no explicit public claim that the digital twin platform itself is FDA- or EMA-cleared medical device software or that it is delivered as a validated GxP system; available material frames AVEVA as an industrial data and compliance enabler rather than a regulated clinical product. | NA |
| Clinical Trial Support | AVEVA publishes an article describing how digital twins and “virtual patients” are revolutionizing drug and medical technology manufacturing and highlights external examples such as Phesi, Sanofi, and Bayer using digital twins for virtual comparators and dose selection in clinical trials, but these are customer or partner use cases and not specific features of an AVEVA-branded clinical trial management or recruitment tool. | NA |
| Supply Chain & Quality | AVEVA Connect and AVEVA PI System collect and analyse real-time production and batch data across manufacturing sites to improve quality control, reduce unplanned downtime, and maintain product consistency, including in pharmaceutical manufacturing, but there is no explicit feature set for counterfeit detection or end-to-end pharma supply chain integrity beyond general industrial asset and process optimisation. | YES |
| Efficiency & Cost-Saving | AVEVA’s Industrial AI, digital twins, and predictive analytics are positioned to automate complex processes, streamline workflows, reduce manual effort, and cut unplanned downtime, with examples such as Biogen reducing quality-control time using AVEVA PI-based predictive models and Vir Biotechnology halving analysis and reporting time via AVEVA analytics dashboards. | YES |
| Scalable / Enterprise-Grade | AVEVA describes its AI-powered digital twins and predictive analytics as scalable across full industrial lifecycles and hundreds of sites, and its PI System and cloud platform are used by large global manufacturers and pharmaceutical companies such as Biogen and Vir Biotechnology, indicating proven enterprise deployment rather than small-scale tools. | YES |
| HIPAA Compliant | Public documentation for AVEVA’s industrial software, PI System, and digital twin offerings focuses on operational and manufacturing data across industries and mentions regulatory compliance in life sciences manufacturing, but there is no explicit statement that the platforms are HIPAA-compliant or designed as healthcare covered-entity systems managing protected health information. | NA |
| Clinically Validated | The material highlights clinical and R&D use of digital twins by pharma companies and academic groups (for example virtual diabetes twins and digital twin hearts), but these examples concern third-party or customer-developed models and do not demonstrate that an AVEVA digital twin product has undergone prospective clinical validation for a defined medical indication. | NA |
| EHR Integration | AVEVA’s platforms emphasise integration with industrial data sources such as SCADA, PLCs, IoT devices, and enterprise systems, and are applied in pharma manufacturing contexts, but there is no indication of native integration with electronic health record systems or clinical information systems used in direct patient care. | NO |
| Explainable AI | AVEVA Predictive Analytics and Industrial AI offerings describe anomaly detection, forecasting, and prescriptive guidance for industrial assets, but public descriptions do not reference formal explainability features such as interpretable models, feature importance reporting, or regulatory-style AI transparency controls aimed at clinicians. | NA |
| Real-Time Analytics | AVEVA Connect, PI System, and predictive analytics products explicitly provide real-time or near-real-time data collection, dashboards, and analytics to monitor KPIs, detect anomalies, and generate alerts across manufacturing and asset operations, including pharma and life sciences environments. | YES |
| Bias Detection | The available documentation for AVEVA digital twins, Industrial AI, and predictive analytics focuses on equipment, process, and operational optimisation and does not mention any capability to identify or document algorithmic bias across patient demographics, clinical sub-cohorts, or similar fairness metrics. | NO |
| Ethical Safeguards | AVEVA notes that its Industrial AI Assistant applies guardrails to restrict questions to industrial use cases and avoid out-of-scope queries, but there is no broader description of healthcare AI governance features such as consent management, explicit human-in-the-loop controls for clinical decisions, or embedded use-case restrictions related to patients. | NA |
Risks & Limitations — AVEVA
-
Predictive and simulation accuracy depend on the quality and completeness of engineering models and live telemetry; incomplete asset models reduce fidelity.
-
Outputs are decision-support; domain experts must validate simulations and operational recommendations.
-
Integration with proprietary control systems, MES, or legacy IT may require significant engineering and IT effort.
-
Large enterprise deployments typically require governance, data-quality programs, and regulatory review in heavily regulated industries (e.g., pharmaceutical manufacturing).
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
